Catalog No.
DHC98501
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
NCAM-1, NCAM1, CD56, N-CAM-1, NCAM, Neural cell adhesion molecule 1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P13591
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BB-10901, IMGN901, huN901-DM1, CAS: 1008106-64-6
Clone ID
Lorvotuzumab
Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma, PMID: 24389179
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study, PMID: 32914879
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models, PMID: 24492307
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma, PMID: 30340993
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program, PMID: 23798344
ADME of antibody-maytansinoid conjugates, PMID: 22875610
Monoclonal antibodies in myeloma, PMID: 26452191
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease, PMID: 28341109
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates, PMID: 26927803
Advances in antibody therapeutics targeting small-cell lung cancer, PMID: 29790694
Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis, PMID: 27935326
Immunoconjugates against solid tumors: mind the gap, PMID: 21368753
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML, PMID: 28321813
NCAM1/FGF module serves as a putative pleuropulmonary blastoma therapeutic target, PMID: 31477684
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients, PMID: 23721099
Emerging antibody-drug conjugates for treating lymphoid malignancies, PMID: 28792782
Drug-conjugated antibodies for the treatment of cancer, PMID: 23173552
Novel formulations and new mechanisms of delivering chemotherapy, PMID: 24857128
Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany, PMID: 22909934
Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies, PMID: 24708159
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors, PMID: 26961907
The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets, PMID: 23239665
For research use only. Not for human or drug use.
